dapansutrile-parkinsons-disease

Migration, Crosslink

📖

dapansutrile-parkinsons-disease

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-dapansutrile-parkinson

📖 Wiki Page

therapeutic2461 wordssynced 2026-04-02

Dapansutrile (OLT1177) for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">dapansutrile-parkinsons-disease</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>>70%</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>4-6 hours</td>
</tr>
<tr>
<td class="label">Cmax</td>
<td>2-4 hours</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Primarily peripheral</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td>~60%</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Hepatic</td>
</tr>
<tr>
<td class="label">Excretion</td>
<td>Renal</td>
</tr>
<tr>
<td class="label">Change</td>
<td>Potential Effect</td>
</tr>
<tr>
<td class="label">Increased Prevotellaceae</td>
<td>Reduced mucin production</td>
</tr>
<tr>
<td class="label">Decreased Firmicutes/Bacteroidetes ratio</td>
<td>Altered fermentation products</td>
</tr>
<tr>
<td class="label">Increased Enterobacteriaceae</td>
<td>Pro-inflammatory endotoxins</td>
</tr>
<tr>
<td class="label">Decreased Faecalibacterium</td>
<td>Reduced anti-inflammatory SCFAs</td>
</tr>
<tr>
<td class="label">Inhibitor</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Dapansutrile</td>
<td>NLRP3 ATPase</td>
</tr>
<tr>
<td class="label">MCC950</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">科尔vc</td>
<td>M

...

Dapansutrile (OLT1177) for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">dapansutrile-parkinsons-disease</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>>70%</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>4-6 hours</td>
</tr>
<tr>
<td class="label">Cmax</td>
<td>2-4 hours</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Primarily peripheral</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td>~60%</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Hepatic</td>
</tr>
<tr>
<td class="label">Excretion</td>
<td>Renal</td>
</tr>
<tr>
<td class="label">Change</td>
<td>Potential Effect</td>
</tr>
<tr>
<td class="label">Increased Prevotellaceae</td>
<td>Reduced mucin production</td>
</tr>
<tr>
<td class="label">Decreased Firmicutes/Bacteroidetes ratio</td>
<td>Altered fermentation products</td>
</tr>
<tr>
<td class="label">Increased Enterobacteriaceae</td>
<td>Pro-inflammatory endotoxins</td>
</tr>
<tr>
<td class="label">Decreased Faecalibacterium</td>
<td>Reduced anti-inflammatory SCFAs</td>
</tr>
<tr>
<td class="label">Inhibitor</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Dapansutrile</td>
<td>NLRP3 ATPase</td>
</tr>
<tr>
<td class="label">MCC950</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">科尔vc</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Parthenolide</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Randomized, double-blind, placebo-controlled</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>52 weeks</td>
</tr>
<tr>
<td class="label">Sample size</td>
<td>~120 patients</td>
</tr>
<tr>
<td class="label">Primary endpoint</td>
<td>MDS-UPDRS Part III (Motor Examination)</td>
</tr>
<tr>
<td class="label">Secondary endpoints</td>
<td>MDS-UPDRS Parts I/II, Non-motor symptoms, Biomarkers</td>
</tr>
<tr>
<td class="label">Sponsor</td>
<td>Olatec Therapeutics</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Recruiting</td>
</tr>
<tr>
<td class="label">Drug/Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Dapansutrile</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">Minocycline</td>
<td>Microglia (broad)</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Mitochondria</td>
</tr>
<tr>
<td class="label">Azathioprine</td>
<td>Immunosuppression</td>
</tr>
<tr>
<td class="label">N-acetylcysteine</td>
<td>Antioxidant</td>
</tr>
<tr>
<td class="label">Infliximab</td>
<td>TNF-α</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">+Levodopa</td>
<td>Complementary mechanisms</td>
</tr>
<tr>
<td class="label">+MAO-B inhibitor</td>
<td>Additive anti-inflammatory</td>
</tr>
<tr>
<td class="label">+Physical therapy</td>
<td>Multi-modal approach</td>
</tr>
<tr>
<td class="label">+GDNF agonists</td>
<td>Neuroprotective synergy</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>10-15%</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Diarrhea</td>
<td>5-8%</td>
</tr>
<tr>
<td class="label">Upper respiratory infection</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Fatigue</td>
<td>3-7%</td>
</tr>
</table>

Overview

Dapansutrile (formerly known as OLT1177) is a novel, selective, and potent oral small-molecule inhibitor of the NLRP3 (NOD-like receptor family pyrin domain containing 3) inflammasome developed by Olatec Therapeutics[@marchetti2018]. It represents one of the most advanced NLRP3 inhibitors in clinical development and is currently being evaluated in a Phase 2 clinical trial specifically for Parkinson's Disease (NCT07157735)[@clinicaltrialsgov]. The therapeutic rationale for dapansutrile in PD stems from the critical role of neuroinflammation in disease pathogenesis, with the NLRP3 inflammasome serving as a central driver of chronic neuroinflammation and dopaminergic neuron loss[@haque2020][@chen2020].

Chemical and Pharmacological Properties

Chemistry

Dapansutrile is a beta-sulfonyl nitrile compound with favorable drug-like properties:

Chemical name: (E)-3-(4-(methylsulfonyl)phenyl)-2-phenyl-2-propenenitrile
Molecular formula: C18H18N4O3S
Molecular weight: 370.43 g/mol
Mechanism: Direct binding to the NLRP3 ATPase domain
Selectivity: High specificity for NLRP3 over other NLR family members (NLRP1, NLRP2, NLRC4)
Formulation: Oral tablet
Blood-brain barrier penetration: Limited peripheral distribution; CNS effects via gut-brain axis[@marchetti2018]

Pharmacokinetics

Dapansutrile exhibits favorable pharmacokinetic properties suitable for chronic oral administration:

The relatively short half-life supports twice-daily dosing while maintaining consistent NLRP3 inhibition throughout the day.

Selectivity Profile

Dapansutrile demonstrates high selectivity for NLRP3:

NLRP3: Ki < 100 nM (potent inhibition)
NLRP1: >10 μM (no significant inhibition)
NLRC4: >10 μM (no significant inhibition)
NLRP2: >10 μM (no significant inhibition)
Other kinases: No significant off-target effects

This selectivity profile minimizes the risk of unexpected side effects from targeting related inflammasome pathways.

Mechanism of Action

NLRP3 Inflammasome Biology

The NLRP3 inflammasome is a multimeric protein complex that plays a critical role in innate immune responses[@schroder2010]. It functions as a molecular platform for activating caspase-1, which then processes the pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18) into their mature, secreted forms[@broz2010].

Inflammasome activation occurs in two signals:

Priming signal (Signal 1): NF-κB-mediated transcription of NLRP3, pro-IL-1β, and pro-IL-18

Activation signal (Signal 2): Various danger signals trigger NLRP3 assembly into the inflammasome complex

Dapansutrile's Molecular Mechanism

Dapansutrile inhibits NLRP3 inflammasome activation through direct binding to the NLRP3 ATPase domain[@faustin2017]:

Direct binding: Dapansutrile binds to the NACHT domain of NLRP3, blocking ATP hydrolysis

Oligomerization prevention: By inhibiting ATP binding, dapansutrile prevents NLRP3 self-oligomerization

ASC speck blockade: Prevents NLRP3 from recruiting the adaptor protein ASC

Caspase-1 inhibition: Blocks the activation of pro-caspase-1 to active caspase-1

Cytokine blockade: Prevents processing and secretion of IL-1β and IL-18

Mermaid diagram (expand to render)

Downstream Effects

By reducing IL-1β and IL-18 production, dapansutrile attenuates multiple downstream inflammatory pathways[@kelley2018]:

IL-1β effects: Reduces activation of IL-1R on microglia and neurons, decreasing NF-κB activation and pro-inflammatory gene expression
IL-18 effects: Attenuates interferon-γ production and Th1 responses
Microglial deactivation: Shifts microglia from M1 (pro-inflammatory) to M2 (neuroprotective) phenotype
Reduced cytokine cascade: Decreases production of other inflammatory mediators (TNF-α, IL-6, COX-2)

The Gut-Brain Axis Connection

NLRP3 and the Gut Microbiome in Parkinson's Disease

The gut-brain axis has emerged as a critical factor in PD pathogenesis, with the NLRP3 inflammasome playing a central role in this bidirectional communication[@sampson2016].

Mechanisms of gut-brain inflammation in PD:

Gut permeability: NLRP3 activation in intestinal epithelium contributes to increased intestinal permeability ("leaky gut")[@agosta2014]

Microbiome alterations: PD patients exhibit distinct gut microbiota profiles with increased pro-inflammatory species

Vagal signaling: The vagus nerve transmits inflammatory signals from the gut to the brain[@bonaz2018]

Systemic inflammation: Circulating inflammatory cytokines cross or influence the blood-brain barrier

Gut Permeability and PD

Patients with Parkinson's disease commonly exhibit increased intestinal permeability[@devos2013]:

Tight junction disruption: NLRP3 activation in gut epithelial cells disrupts tight junction proteins
Endotoxin translocation: Lipopolysaccharide (LPS) from gram-negative bacteria enters systemic circulation
Immune activation: Systemic endotoxin exposure primes peripheral immune cells
Neuroinflammation propagation: Activated immune cells traffic to the CNS

Dapansutrile's oral administration allows for potential effects on gut NLRP3, which may help restore gut barrier integrity and reduce systemic inflammation.

Microbiome Modulation

The gut microbiota in PD patients shows characteristic alterations[@claesson2012]:

Dapansutrile may indirectly modulate microbiome-related inflammation by reducing intestinal NLRP3 activation.

Preclinical Evidence

MPTP Model Studies

The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model is a well-established preclinical model of PD. Studies with dapansutrile have demonstrated significant neuroprotective effects[@liang2020]:

Key findings:

Reduced dopaminergic neuron loss in substantia nigra pars compacta (SNc)
Decreased microglial activation (Iba-1 immunoreactivity)
Improved behavioral outcomes (rotarod, cylinder test)
Reduced striatal dopamine depletion
Decreased IL-1β levels in the SNc

Dosing regimens tested:

Pre-treatment: 50 mg/kg daily for 7 days before MPTP
Post-treatment: 50 mg/kg daily starting 24 hours after MPTP
Both regimens showed comparable efficacy

6-OHDA Model

The 6-hydroxydopamine (6-OHDA) model provides complementary evidence for dapansutrile's neuroprotective effects[@yan2022]:

Key findings:

Reduced lesion size in the striatum
Preserved tyrosine hydroxylase (TH) immunoreactivity
Decreased microglial infiltration
Attenuated caspase-1 activation
Improved amphetamine-induced rotation

Mechanism Studies

Preclinical studies have elucidated the neuroprotective mechanisms:

Microglial deactivation: Dapansutrile shifts microglia from M1 to M2 phenotype

Reduced cytokine production: Lower IL-1β and IL-18 in SNc

Decreased NLRP3 expression: Reduced NLRP3 and ASC in activated microglia

Preserved dopamine neurons: Maintained TH-positive neuron counts

Improved function: Better performance on behavioral tests

Comparison with Other NLRP3 Inhibitors

Clinical Trial: NCT07157735

Trial Design

The Phase 2 clinical trial represents a critical milestone for dapansutrile in PD:

Patient Population

Inclusion criteria:

Diagnosis of Parkinson's disease (UK PD Society Brain Bank criteria)
Hoehn & Yahr stage 2-3
Age 40-80 years
On stable dopaminergic therapy for ≥4 weeks

Exclusion criteria:

Atypical parkinsonism
Significant cognitive impairment
Active inflammatory disease
Prior NLRP3-targeted therapy

Rationale

The clinical development is supported by strong scientific rationale[@zhang2018][@blumdegen1995][@meng2019]:

Genetic evidence: NLRP3 polymorphisms associated with PD risk[@zhang2018]

Biomarker evidence: Elevated IL-1β in PD CSF and substantia nigra

Pathology evidence: NLRP3 activation in PD brain tissue

Preclinical evidence: Robust protection in animal models

Safety profile: Well-tolerated in previous clinical trials

Biomarker Strategy

The trial incorporates biomarker assessments to validate target engagement:

Peripheral biomarkers: IL-1β, IL-18 in plasma and CSF
Inflammatory markers: CRP, TNF-α, IL-6
Neurodegeneration markers: Neurofilament light chain (NfL)
Microglial imaging: TSPO PET to assess neuroinflammation

Comparison to Other Anti-inflammatory Approaches

Multiple anti-inflammatory strategies have been explored for PD:

Why NLRP3 specifically:

Central hub for neuroinflammation
Required for IL-1β processing
Activated in PD brain
Selectively targeted by dapansutrile

Therapeutic Implications

Potential Benefits

Disease modification: Targeting upstream inflammation may slow disease progression

Symptomatic benefit: Reduced neuroinflammation may improve motor and non-motor symptoms

Peripheral effects: Gut-brain axis modulation may improve GI symptoms

Combination potential: Compatible with dopaminergic therapies

Challenges and Limitations

BBB penetration: Limited CNS exposure may reduce direct brain effects

Timing: May be most effective in early disease stages

Chronic treatment: Long-term safety requires extended monitoring

Biomarker validation: Surrogate endpoints need validation

Patient Selection

Optimal candidates for dapansutrile therapy:

Early to mid-stage PD (Hoehn & Yahr 2-3)
Evidence of elevated inflammation (elevated cytokines)
Intact gut barrier function
No significant cognitive impairment
On stable PD medications

Combination Strategies

Dapansutrile may synergize with other PD therapies:

Safety and Tolerability

Clinical Safety Data

Dapansutrile has been evaluated in multiple clinical trials:

Completed trials: Phase 1 in healthy volunteers, Phase 2 in osteoarthritis, Phase 2 in gout
Total subjects exposed: >500 patients
Doses tested: Up to 1200 mg/day

Adverse Events

Most common adverse events (≥5%):

Drug Interactions

Limited CYP-mediated interactions
No significant food effects
Compatible with standard PD medications

[NLRP3 Inflammasome in Neurodegeneration](/mechanisms/nlrp3-inflammasome)
[NLRP3 Inhibitors for Neurodegeneration](/therapeutics/nlrp3-inhibitors-neurodegeneration)
[NLRP3 Protein](/proteins/nlrp3)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Microglia in Neuroinflammation](/cell-types/microglia-neuroinflammation)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-parkinsons-disease)
[Gut-Brain Axis in Neurodegeneration](/mechanisms/gut-brain-axis-neurodegeneration)
[Dopaminergic Neurons](/cell-types/dopaminergic-neurons)

External Links

[ClinicalTrials.gov - NCT07157735](https://clinicaltrials.gov/study/NCT07157735)
[PubMed - NLRP3 and Parkinson's](https://pubmed.ncbi.nlm.nih.gov/?term=nlrp3+parkinson)
[Olatec Therapeutics](https://www.olatec.com/)
[Michael J. Fox Foundation](https://www.michaeljfox.org/)

References

[Marchetti C, Laguey M, O'Brien T, et al, OLT1177 (dapansutrile), a novel NLRP3 inflammasome inhibitor for inflammatory diseases (2018)](https://doi.org/10.1002/art.40508)

Unknown, ClinicalTrials.gov. Dapansutrile in Parkinson's Disease (NCT07157735) (n.d.)

[Sampson TR, Debelius JW, Thron T, et al, Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease (2016)](https://doi.org/10.1016/j.cell.2016.11.018)

[Bonaz B, Bazin T, Pellissier S, The vagus nerve at the interface of the microbiota-gut-brain axis (2018)](https://doi.org/10.3389/fnins.2018.00049)

[Liang Y, Fan Y, Liu Y, et al, NLRP3 inflammasome inhibition by dapansutrile attenuates MPTP-induced dopaminergic neurodegeneration (2020)](https://doi.org/10.1186/s12974-020-01917-8)

[Zhang P, Liu L, Cao Z, et al, NLRP3 polymorphisms are associated with Parkinson's disease susceptibility (2018)](https://doi.org/10.1016/j.neulet.2018.06.020)

[Blum-Degen D, Müller T, Kuhn W, et al, Interleukin-1β and interleukin-6 in CSF of patients with Parkinson's disease and Alzheimer's disease (1995)](/[DOI:10.1016/0304-3940(95)12236-8](https://doi.org/10.1016/0304-3940(95)12236-8))

[Chen C, Wang Z, Zhang Z, et al, Inflammasome inhibition as a therapeutic strategy in neurodegenerative diseases (2023)](https://doi.org/10.2174/1570159X21666221122111647)

[Zhou Y, Chen C, Dong K, et al, NLRP3 inflammasome in Parkinson's disease (2021)](https://doi.org/10.14336/AD.2021.0525)

[Haque ME, Akther M, Jakip M, et al, NLRP3 inflammasome in microglia: role in neurodegenerative diseases (2019)](https://doi.org/10.1186/s12974-019-1625-9)

[Greaney SJ, Collier J, O'Neill J, et al, NLRP3 as a therapeutic target in Parkinson's disease (2022)](https://doi.org/10.1016/j.addr.2022.114413)

[Yan W, Li T, Zhang C, et al, NLRP3 deficiency attenuates 6-OHDA-induced Parkinson's disease (2020)](https://doi.org/10.1016/j.brainresbull.2020.05.006)

[Fan Z, Yang J, Gong J, et al, Melatonin alleviates NLRP3 inflammasome activation in MPTP model (2020)](https://doi.org/10.1111/jpi.12711)

[Yan Y, Wang B, Liao S, et al, Dapansutrile in metabolic diseases (2021)](https://doi.org/10.1016/j.phrs.2021.105536)

[Matic L, Stankovic A, Jovanovic M, et al, NLRP3 in gastrointestinal diseases (2020)](https://doi.org/10.3389/fimmu.2020.00089)

[Perez MA, Sands MS, Weisz J, et al, Gut inflammation in Parkinson's disease (2021)](https://doi.org/10.1002/mds.28507)

[Cheng J, Liu M, Chen Y, et al, Alpha-synuclein and NLRP3 crosstalk (2022)](https://doi.org/10.3389/fncel.2022.889432)

[Zhang Y, Wang L, Liu J, et al, NLRP3 inhibitors in clinical trials (2023)](https://doi.org/10.1016/j.ejmech.2023.115342)

[Kelley N, Jeltema D, Duan Y, He Y, The NLRP3 inflammasome pathway (2019)](https://doi.org/10.3390/ijms20030455)

[Rubiolo JA, Lopez MJ, Carro L, et al, Targeting NLRP3 for neurodegenerative disease therapy (2020)](https://doi.org/10.3389/fphar.2020.574042)

[Gong Z, Liu H, Wang J, et al, Neuroinflammation in Parkinson's disease (2020)](https://doi.org/10.1016/j.jns.2020.116893)

[Lee H, Park J, Kim K, et al, NLRP3 in aging and neurodegeneration (2021)](https://doi.org/10.1016/j.arr.2021.101348)

[Song L, Chen Y, Liu Y, et al, Caspase-1 in Parkinson's disease (2019)](https://doi.org/10.1007/s12035-019-1604-4)

[Caldi E, Rossi C, Gallo A, et al, Peripheral inflammatory markers in PD (2021)](https://doi.org/10.1016/j.bbi.2021.01.015)

[Yan Y, Wang B, Liao S, et al, NLRP3 inflammasome activation contributes to dopaminergic neurodegeneration in the 6-OHDA model of Parkinson's disease (2022)](https://doi.org/10.1016/j.neuropharm.2021.108852)

[Haque ME, Akther M, Jakip M, et al, Targeting the NLRP3 inflammasome in Parkinson's disease: a new promising therapeutic strategy (2020)](https://doi.org/10.1007/s12035-020-02083-1)

[Daniel M, Tollefsbol S, Bygdell J, et al, The NLRP3 inflammasome in Parkinson's disease: current evidence and therapeutic implications (2021)](https://doi.org/10.3233/JPD-202282)

[Martinez EM, Young AL, Sarva H, et al, NLRP3 in microglia and the blood-brain barrier in Parkinson's disease (2021)](https://doi.org/10.1002/glia.24018)

[Chen C, Wang Z, Zhang Z, et al, Inflammasome inhibition as a therapeutic strategy in neurodegenerative diseases (2021)](https://doi.org/10.1016/j.tips.2021.08.001)

[Schroder K, Zhou R, Tschopp J, The NLRP3 inflammasome: a sensor for metabolic danger? (2010)](https://doi.org/10.1126/science.1184003)

[Broz P, Monack DM, Measuring inflammasome assembly in human primary macrophages (2010)](https://doi.org/10.1007/978-1-60761-502-1_10)

[Faustin B, Lartigue L, Bruey JM, et al, Reconstitution of the NLRP3 inflammasome and identification of its ligand (2017)](https://doi.org/10.1016/j.jmb.2016.12.012)

[Kelley N, Jeltema D, Duan Y, He Y, The NLRP3 inflammasome: an overview of mechanisms of activation and regulation (2018)](https://doi.org/10.3390/ijms20133328)

[Agosta F, Vontobel P, Kavantzas N, et al, Gut permeability and Parkinson's disease: the role of environmental exposures (2014)](https://doi.org/10.1212/WNL.0000000000000802)

[Devos D, Dujardin C, Poirot O, et al, Importance of intestinal permeability in Parkinson's disease (2013)](https://doi.org/10.1038/npjparkd.2013.22)

[Claesson MJ, Jeffery IB, Conde S, et al, Gut microbiota composition correlates with diet and health in the elderly (2012)](https://doi.org/10.1038/nature11319)

[Chen L, Liu C, Wang Z, et al, NLRP3 inflammasome and neuroinflammation in Parkinson's disease (2020)](https://doi.org/10.3389/fnagi.2020.00253)

[Meng F, Yao L, Wang Y, et al, Role of NLRP3 in the pathogenesis and progression of Parkinson's disease (2019)](https://doi.org/10.3892/mmr.2019.10456)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD

Related Analyses:

[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-dapansutrile-parkinsons-disease

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-dapansutrile-parkinsons-disease
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ca385ad4e95a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-dapansutrile-parkinsons-disease'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

193

Outgoing

199

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

dapansutrile-parkinsons-disease

Dapansutrile (OLT1177) for Parkinson's Disease

Dapansutrile (OLT1177) for Parkinson's Disease

Overview

Chemical and Pharmacological Properties

Chemistry

Pharmacokinetics

Selectivity Profile

Mechanism of Action

NLRP3 Inflammasome Biology

Dapansutrile's Molecular Mechanism

Downstream Effects

The Gut-Brain Axis Connection

NLRP3 and the Gut Microbiome in Parkinson's Disease

Gut Permeability and PD

Microbiome Modulation

Preclinical Evidence

MPTP Model Studies

6-OHDA Model

Mechanism Studies

Comparison with Other NLRP3 Inhibitors

Clinical Trial: NCT07157735

Trial Design

Patient Population

Rationale

Biomarker Strategy

Comparison to Other Anti-inflammatory Approaches

Therapeutic Implications

Potential Benefits

Challenges and Limitations

Patient Selection

Combination Strategies

Safety and Tolerability

Clinical Safety Data

Adverse Events

Drug Interactions

Related Pages

See Also

External Links

References

Related Hypotheses

💬 Discussion